Skip to content

Study · Animal study (in vivo) · mouse · 2018

3 results

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.

Cai HY, Yang JT, Wang ZJ, Zhang J, Yang W, Wu MN, Qi JS

Biochemical and biophysical research communications22 Nov 2017Cited by 86 (Europe PMC)

PMID29175324 (opens in a new tab)DOI10.1016/j.bbrc.2017.11.114 (opens in a new tab)PepBankPUB-29175324
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In APP/PS1/tau female mice, lixisenatide could reduce hippocampal amyloid plaques, neurofibrillary tangles and neuroinflammation.

    In plain wordsIn mice, lixisenatide could reduce brain amyloid plaques, neurofibrillary tangles and inflammation.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAmyloid plaques, tangles and neuroinflammation
    Study

    mousen: not reported in source

    APP/PS1/tau female mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    The results showed that lixisenatide could reduce amyloid plaques, neurofibrillary tangles and neuroinflammation in the hippocampi of 12-month-old APP/PS1/tau female mice;
    1 context sentence
    Summary · context
    In the follow-up study, we analysed the neuroprotective effect and mechanism of lixisenatide, injected for 60 days at 10 nmol/kg i.p. once daily in APP/PS1/tau female mice and C57BL/6J female mice (as control) aged 12 month.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In APP/PS1/tau female mice, PKA-CREB activation might contribute to lixisenatide neuroprotection.

    In plain wordsIn mice, activation of PKA-CREB signaling might contribute to lixisenatide's brain protection.

    Peptide
    Lixisenatide
    Outcome
    IncreasePKA-CREB signaling
    Study

    mousen: not reported in source

    APP/PS1/tau female mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    activation of PKA-CREB signaling pathway and inhibition of p38-MAPK might be the important mechanisms in the neuroprotective function of lixisenatide.
    1 context sentence
    Summary · context
    In the follow-up study, we analysed the neuroprotective effect and mechanism of lixisenatide, injected for 60 days at 10 nmol/kg i.p. once daily in APP/PS1/tau female mice and C57BL/6J female mice (as control) aged 12 month.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In APP/PS1/tau female mice, p38-MAPK inhibition might contribute to lixisenatide neuroprotection.

    In plain wordsIn mice, inhibition of p38-MAPK signaling might contribute to lixisenatide's brain protection.

    Peptide
    Lixisenatide
    Outcome
    Decreasep38-MAPK signaling
    Study

    mousen: not reported in source

    APP/PS1/tau female mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    activation of PKA-CREB signaling pathway and inhibition of p38-MAPK might be the important mechanisms in the neuroprotective function of lixisenatide.
    1 context sentence
    Summary · context
    In the follow-up study, we analysed the neuroprotective effect and mechanism of lixisenatide, injected for 60 days at 10 nmol/kg i.p. once daily in APP/PS1/tau female mice and C57BL/6J female mice (as control) aged 12 month.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.